Inovio Pharmaceuticals stock faces FDA decision for INO-3107

Published on 10/30/2026 at 20:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inovio Pharmaceuticals stock remains focused on the FDA review of INO-3107. The decision concerns a rare respiratory disease.

FDA timing and pipeline focus

INO-3107 is under FDA review for adults with recurrent respiratory papillomatosis.
The FDA action date for the application is October 30, 2026.
The regulatory decision remains the key near-term event for Inovio Pharmaceuticals.

INO, US45773H4092, Illustration mit AI erstellt.

Inovio Pharmaceuticals is approaching a regulatory decision that could shape the next phase of its development program. The U.S. Food and Drug Administration is scheduled to act by October 30, 2026, on the company's Biologics License Application for INO-3107, according to RTTNews in a report published October 28.

FDA decision remains the catalyst

INO-3107 is being reviewed as a potential treatment for adults with recurrent respiratory papillomatosis, or RRP. RTTNews described RRP as a rare disease caused primarily by HPV-6 and HPV-11, with wart-like tumors developing in the respiratory tract and potentially affecting breathing and speech.

Patients with RRP often require repeated operations to remove the growths because they can return. The FDA action therefore represents a significant clinical and commercial milestone for Inovio, although the regulatory outcome itself remains the immediate question for investors.

Stock quote reflects event risk

Inovio Pharmaceuticals stock traded at 0.56 euros on Lang & Schwarz at 20:44 CET on Friday, October 30, 2026.

Investors should distinguish the scheduled FDA action from any later commercial consequences. Approval, a request for additional work or another regulatory outcome would affect the development timetable differently, while the company's ability to advance beyond this decision would remain relevant to the longer-term investment case.

For the latest trading indication, see the real-time quote of Inovio Pharmaceuticals stock.

The broader market backdrop is provided by the S&P 500.

Further developments can be followed in more news and analyses on Inovio Pharmaceuticals stock.